Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT02553707
An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT02552940
- Locations
- 🇧🇪
ASZ Aalst, Aalst, Belgium
🇧🇪Reumacentrum Genk, Genk, Belgium
🇧🇪AZ Damiaan, Oostende, Belgium
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Other: No intervention
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT02552849
- Locations
- 🇨🇦
Edmonton Respiratory Consultants & Edmonton Sleep Lab, Edmonton, Alberta, Canada
🇨🇦Kelowna Respiratory and Allergy Cllinic, Kelowna, British Columbia, Canada
🇨🇦Mainra Rajesh R, Respirology, North Vancouver, British Columbia, Canada
A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Other: placeboBiological: PRM-151
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT02550873
- Locations
- 🇩🇪
Justus-Liebig University Giessen, Giessen, Germany
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UT - Southwestern Medical School, Dallas, Texas, United States
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 126
- Registration Number
- NCT02550652
- Locations
- 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸Univ of California, San Diego, La Jolla, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Study of Intravenous RXDX-107 in Patients With Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: RXDX-107
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT02548390
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Johns Hopkins Medical Institute, Baltimore, Maryland, United States
🇺🇸Tennessee Oncology, LLC, Nashville, Tennessee, United States
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: LebrikizumabDrug: Placebo
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 309
- Registration Number
- NCT02546700
- Locations
- 🇺🇸
Centex Studies, Houston, Texas, United States
🇺🇸Comprehensive Clinical Research Inc., Berlin, New Jersey, United States
🇺🇸Clinical Research Inst. of Southern Oregon, Pc, Medford, Oregon, United States
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02546869
An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)
- Conditions
- Kidney Disease, Chronic
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 393
- Registration Number
- NCT02547454
- Locations
- 🇸🇮
Hospital Celje; Dept For Kidney Disease & Dialysis, Celje, Slovenia
🇸🇮Splosna Bolnisnica Izola; Oddelek Za Nefrologijo, Izola, Slovenia
🇸🇮Clinical Centre Ljubljana; Clinical Dep. For Nephrology, Ljubljana, Slovenia
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: 23-PPVBiological: 13-PCV BoosterBiological: Influenza VaccineBiological: KLHDrug: OCRBiological: TT Vaccine
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT02545868
- Locations
- 🇺🇸
The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Territory Neurology and Research Institute, Tucson, Arizona, United States
🇺🇸North Central Neurology Associates, Cullman, Alabama, United States